Targeted therapy against ROS A synthetic antioxidant regimen has been established with four main approaches: lipid-lowering, blood pressure-lowering, thiol supplementation, and enzyme replacement Statins block the mevalonate pathway by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, reduce Rac1 membrane translocation, thereby lowering ROS derived from NOX, while stabilizing eNOS mRNA, increasing NO bioavailability, and inhibiting various adhesion molecules, achieving a dual suppression of oxidative stress and inflammation [486]
Targeting MST1 or its downstream effectors involved in ROS regulation might lead to novel strategies for modulating pyroptosis and its associated inflammatory consequences
19 WaespeNStrebelSJurkovic MlakarSKrajinovicMKuehniCENavaTet al
References Lamptey RNL, Chaulagain B, Trivedi R et al (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics
This differential role depends on their ability to confer different properties to adrenergic 2A receptor ( 2A R)-D 4 R heteromers and dopamine D 2 receptor (D 2 R)-D 4 R heteromers, preferentially localized in the perisomatic region of the frontal cortical pyramidal neuron and its striatal terminals, respectively
